CD8A and cancer: As the results showed, although the release of cancer antigens (step1) and cancer antigen presentation (step2) were enhanced in BASP1high patients, there was no significant difference in the priming and activation (step 3) was identified between these two groups, indicating that the reduced CD8+ T cells infiltration was due to a dysfunction of immune cell priming and activation activity in BASP1high patients (Figure 6A).